Multi-targeted approach in the treatment of thyroid cancer

Minerva Chirurgica

Volumn 65, Issue 1, 2010, Pages 59-69

  Zarebczan, B ^a   Chen, H ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Drag therapy; Thyroid neoplasm, diagnosis; Thyroid neoplasms, surgery

Indexed keywords

GENETICS; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; THYROID TUMOR;

COMBINED MODALITY THERAPY; HUMANS; THYROID NEOPLASMS;

EID: 77952934041     PISSN: 00264733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. UK Cancer Research. [Accessed 2009 December 10; cited 2010 January 22]. Available at: http://info.can-cerresearchuk.org/cancerstats/types/thyroid/ inciden-ce/uk-thyroid-cancer-incidence-statistics.
3. Davies L, Welch H. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295:2164-7.
4. Ito Y, Tomoda C, Urtino T, Takamura Y, Miya A, Kobayashi K et al. Preoperative ultrasonographic exa-mination for lymph node metastasis: usefulness when designing lymph node dissection for papillary micro-carcinoma of the thyroid. World J Surg 2004;28:498-501.
5. Ball DW. Medullary Thyroid Cancer. In: Wondisford FE RS, ed. Clinical Management of Thyroid Disease: Saunders; 2009. p. 399-405.
6. Sherman SI. Thyroid Carcinoma. Lancet 2007;361:501-11.
7. Gilliland F, Hunt W, Morris D, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15, 698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-73.
8. Dean D, Hay I. Prognostic indicatore in differentiated thyroid carcinoma. Cancer Control 200;7:229-39.
9. Sanders L, Cady B. Differentiated thyroid cancer: reexa-mination of risk groups and outcome of treatment. Arch Surg 1998;133:419-25. (Pubitemid 28193527)
10. Verburg FA, Mäder U, Kruitwagen CL, Luster M, Reiners C. A comparison of prognostic classification systems for differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2009 [Epub ahead of print].
11. Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999;16:34-41.
12. Udelsman R, Chen H. The current management of thyroid cancer. Adv Surg 1999;33:1-27.
13. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167-214.
14. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375-81; discussion 381-4.
15. Mazzaferri E, Young R. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-8.
16. DeGroot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH. Naturai history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-24.
17. Grebe S, Hay I. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:43-63.
18. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134:946-54; discussion 954-5.
19. Simon D, Goretzki PE, Witte J, Röher HD. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg 1996;20:1860-6; discussion 866.
20. Podnos YD, Smith D, Wagman LD, Ellenhorn JD. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005;71:731-4.
21. Greenblatt D, Elson D, Mack E, Chen H. Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg 2007;30:108-12.
22. Sippel R, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist 2008;13:539-47.
23. Moley J, DeBenedetti M. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommen-dations for extent of node dissection. Ann Surg 1999;229:880-7; discussion 887-8.
24. Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 2007;31(10):1960-5.
25. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-71.
26. Chi D, Moley J. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with pereistent hypercalcitoninemia. Surg Oncol Clin N Am 1998;7:681-706.
27. Sherrman SI. Anaplastic carcinoma: clinical aspeets. In: L W, ed. Thyroid cancer: a comprehensive guide to clinical management. Totowa, NJ: Humana Press; 1999. p. 319-25.
28. Pierie JP, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57-64.
29. Mazzaferri E, Jhiang S. Long-term impact of initial surgical and medicai therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
30. Hay I, Hutchinson M, Gonzalez-Losada T, Mclver B, Reinalda ME, Grant CS et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008;144:980-7; discussion 987-8.
31. Ross D, Litofsky D, Ain K, Bigos T, Brierley JD, Cooper DS et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid 2009;19:1043-8.
32. Pinchot SNSR, Chen H. Multi-targeted approach in the treatment of thyroid cancer. Therapeutics and Clinical Risk Management 2008;4:935-47.
33. Shiba E, Miyauchi K, Kobayashi T, Takai S, Mori T. [The effect of thyroid hormone on the growth of thyroid cancer]. Gan To Kagaku Ryoho 1989;16:3678-84.
34. Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005;1:32-40.
35. Bauer D, Nevitt M, Ettinger B, et al. Low thyrotropin levels are not associated with bone loss in older women: a prospettive study. J Clin Endocrinol Metab 1997;82:2931-6.
36. Pujol P, Daures J, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318-23.
37. Cooper D, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-44.
38. National Cancer Institute Surveillance Epidemiology and End Results Database. US National Institutes of Health. Available at: http://seer.cancer. gov/stat-facts/html/thyro.html. Accessed December 8, 2009.
39. Nikiforov Y. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008;21 Suppl 2: S37-43.
40. Kimura E, Nikiforova M, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive attivation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
41. Yeh M, Rougier J, Park J, Duh QY, Wong M, Werb Z et al. Differentiated thyroid cancer cell invasion is regu-lated through epidermal growth factor receptor-depen-dent attivation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 2006;13:1173-83.
42. Kunnimalaiyaan M, Vaccaro A, Ndiaye M, Chen H. Inactivation of glycogen synthase kinase-3beta, a down-stream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007;6:1151-8.
43. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist 2007;12:535-42.
44. Nikiforova M, Lynch R, Biddinger P, Alexander EK, Dorn GW 2nd, Tallini G et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318-26.
45. Mulligan L, Marsh D, Robinson B, Schuffenecker I, Zedenius J, Lips CJ et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995;238:343-6.
46. Hansford J, Mulligan L. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000;37:817-27.
47. Santoro M, Melillo R, Carlomagno F, Visconti R, De Vita G, Salvatore G et al. Molecular biology of the MEN2 gene. J Intern Med 1998;243:505-8.
48. Knauf J, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 2003;22:4406-12.
49. Melillo R, Castellone M, Guarino V, De Falco V, Cirafici AM, Salvatore G et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005;115:1068-81.
50. Mitsutake N, Knauf J, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chro-mosomal instability in thyroid PCCL3 cells. Cancer Res 2005;65:2465-73.
51. Adeniran A, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ et al. Correlation between genetic altera-tions and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary car-cinomas. Am J Surg Pathol 2006;30:216-22.
52. Herbst R, Heymach J, O'Reilly M, Onn A, Ryan AJ. Vandetanib (ZD6474) : an orally available receptor tyro-sine kinase inhibitor that selectively targets pathways criticai for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007;16:239-49.
53. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-90.
54. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2006;2:42-52.
55. Sherman S. Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am 2008;37:511-24.
56. Coxon A, Bready J, Fiorino M, et al. Anti-tumor activity of AMG 706, an oral multi-kinase inhibitor, in human medullary thyroid carcinoma xenografts. Thyroid 2006;16:920.
57. Rosen L, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369-76.
58. Schlumberger M, Elisei R, Sherman SI, et al. Phase 2 trial of motesanib diphosphate (AMG 706) in patients with medullary thyroid cancer (MTC). Presented at 89th Annual Meeting of the Endocrine Society. Toronto (ON), June 2007.
59. Smallridge R, Marlow L, Copland J. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:17-44.
60. Ciampi R, Nikiforov Y. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005;16:163-72.
61. Nikiforova M, Kimura E, Gandhi M, Biddinger PW, Knauf JA, Basolo F et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
62. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-7.
63. Xing M, Westra W, Tufano R, Cohen Y, Rosenbaum E, Rhoden KJ et al. BRAF mutation prediets a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9.
64. Kim T, Kim W, Rhee Y, Song JY, Kim JM, Gong G et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65:364-8.
65. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12:1623-9.
66. Baudin E, Schlumberger M. New therapeutic approa-ches for metastatic thyroid carcinoma. Lancet Oncol 2007;8:148-56.
67. Espinosa A, Porchia L, Ringel M. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96:16-20.
68. Braga-Basaria M, Ringel M. Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 2003;88:1947-60.
69. Akslen L, Myking A, Salvesen H, Varhaug JE. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer 1993;68:808-12. (Pubitemid 23301291)
70. Holting T, Siperstein A, Clark O, Duh QY. Epidermal growth factor (EGF) - and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 1995;132:229-35.
71. Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res 1997;17(4B):3157-9.
72. Pietras R, Fendly B, Chazin V, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829-38.
73. Yoon K, Gaiano N. Notch signaling in the mammalian centrai nervous system: insights from mouse mutants. Nat Neurosci 2005;8:709-15.
74. Kunnimalaiyaan M, Haymart M, Chen H. Tumor sup-pressor role of Notch-1 and Raf-1 signaling in medullary thyroid cancer cells. Translational Ocogenomics 2007;2:43-7.
75. Ning L, Greenblatt D, Kunnimalaiyaan M, Chen H. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist 2008;13:98-104. (Pubitemid 351342572)
76. Greenblatt D, Cayo M, Adler J, Ning L, Haymart MR, Kunnimalaiyaan M et al. Valproic acid activates Notchl signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 2008;247:1036-40. (Pubitemid 351770425)
77. Xiao X, Ning L, Chen H. Notch1 mediates growth sup-pression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol Cancer Ther 2009;8:350-6.
78. Hardt S, Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and deve-lopment. Circ Res 2002;90:1055-63.
79. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2:769-76.
80. Adler J, Cook M, Luo Y, Pitt SC, Ju J, Li W et al. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther 2009;8:914-20.
81. Cunningham C, Holmlund J, Geary R, Kwoh TJ, Dorr A, Johnston JF et al. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 2001;92:1265-71.
82. Kroll T, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM et al. PAX8-PPARgammal fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357-60.
83. French C, Alexander E, Cibas E, Nose V, Laguette J, Faquin W et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003;162:1053-60.
84. Dwight T, Thoppe S, Foukakis T, Lui WO, Wallin G, Höög A et al. Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab 2003;88:4440-5.
85. Gregory Powell J, Wang X, Allard B, Allard BL, Sahin M, Wang XL et al. The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thy-rocytes through a mechanism probably involving wild-type PPARgamma inhibition. Oncogene 2004;23:3634-41.
86. Giordano T, Au A, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 2006;12(7 Pt 1):1983-93.
87. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, Clark OH et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006;140:960-6; discussion 966-7.